Additionally, the selective USP7 inhibitor FT671 induced significant cytotoxicity in PDCs (Fig. S9), highlighting USP7 targeting as a promising therapeutic strategy for TP53-mutant, r/r DLBCL. The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.